Mink Therapeutics
agent in solid tumors and covid mink | Mink Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2022
Slide
73 of 92
Related slides by other companies
Kymera
Investor Day
December 2021
degrader first in class opportunity to address driven pathology across diverse indications first degrader against an undrugged target in the clinic profound single agent activity in liquid tumor and promising activity with anti in liquid and solid tumors clinical development strategy includes direct registrational path in pathway activated heme malignancies opportunity for expansion into solid tumors in combination with immune inhibitors | Kymera
Enochian Biosciences
Investor Presentation
January 2024
procedural flow patient manufacturing site patient | Enochian Biosciences
BioNTech
Results
August 2021
acquisition of kite solid tumor cell platform and related assets | BioNTech
RayzeBio
IPO
September 2023
extended imaging with shows tumor retention | RayzeBio
Other recent decks by Mink Therapeutics
See all presentations (2 decks)
IPO
October 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights